Research Topic

Angiogenesis and Angiogenesis Inhibitors in Oral Cancer

About this Research Topic

Oral squamous cell carcinoma (OSCC), is the 17th most prevalent cancer worldwide. OSCC incidence is globally increasing, and despite improvements in treatment, it is still characterized by rather poor survival. Currently, primary treatment of OSCC patients consists of surgery and (chemo) radiotherapy, either ...

Oral squamous cell carcinoma (OSCC), is the 17th most prevalent cancer worldwide. OSCC incidence is globally increasing, and despite improvements in treatment, it is still characterized by rather poor survival. Currently, primary treatment of OSCC patients consists of surgery and (chemo) radiotherapy, either alone or in combination. Other approaches, such as targeted- and immunotherapy, also represent approved modalities, although they remain inconsistently applied as first-line treatment for OSCC patients. Unfortunately, these treatments offer limited efficacy, with a five-year survival among OSCC patients reaching ~50%.

Angiogenesis is a hallmark of cancer and it is crucial for tumor growth, invasion, and metastasis formation. Several pathways are involved in mediating angiogenesis, and vascular endothelial growth factor (VEGF) pathway is the most important one. Two major categories of agents have been developed to target VEGF pathway: antibody-based agents and VEGF receptor tyrosine kinase inhibitors (TKIs). Antiangiogenic agents have been approved by the US Food and Drug Administration (US-FDA) for treating solid tumors, including colorectal cancer, renal cell carcinoma, ovarian cancer, gastric cancer, and thyroid cancer. OSCC is a highly vascularized tumor but despite the crucial role of angiogenesis in OSCC, there is no antiangiogenic agent in clinical use and no vascular marker is approved as prognostic marker for this patient population. However, the knowledge in this field is still growing and there is large hope of further development. The promising clinical trials results of endostatin (an angiogenesis inhibitor) is a good example of this.

This Research Topic will cover topics related to angiogenesis and tumor related vessels in oral cancer. We hope to provide the most recent and novel knowledge in this growing field.

We welcome high-quality original research articles and reviews involving observational and experimental data of basic and clinical research. The scope includes different areas of interest, such as, but not limited to: epidemiology, clinics, histopathology, immunohistochemistry, bioinformatics, digital pathology, cell and molecular biology (including genomics, epigenomics, transcriptomics, proteomics and metabolomics).

Studies are not limited to oral squamous cell carcinomas, since studies involving tumors of the head and neck area will also be considered.

Image credit: http://www.scientificanimations.com/wiki-images/


Keywords: oral cancer, angiogenesis, vessels, angiogenesis inhibitors, biomarkers


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Recent Articles

Loading..

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

16 May 2021 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..

Topic Editors

Loading..

Submission Deadlines

16 May 2021 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..